Compare · IZTC vs SGEN
IZTC vs SGEN
Side-by-side comparison of Invizyne Technologies Inc. (IZTC) and Seagen Inc. (SGEN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IZTC and SGEN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- SGEN carries a market cap of $23.34B.
- SGEN has more recent analyst coverage (25 ratings vs 0 for IZTC).
- Company
- Invizyne Technologies Inc.
- Seagen Inc.
- Price
- $17.40-0.57%
- $228.86-0.01%
- Market cap
- -
- $23.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2001
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 25
Seagen Inc.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Latest IZTC
- Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
- Invizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
- Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)
- Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)
- SEC Form 3 filed by new insider Bell Lon E
- Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
- SEC Form SC 13D filed by Invizyne Technologies Inc.
- SEC Form SC 13D filed by Invizyne Technologies Inc.
- SEC Form SC 13D filed by Invizyne Technologies Inc.
Latest SGEN
- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- Alltrna Announces Updates to Its Board of Directors
- Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
- How To Earn $500 A Month From Pfizer Stock
- Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
- SEC Form 15-12G filed by Seagen Inc.
- Baker Bros. Advisors Lp returned $10,248,908,740 worth of shares to the company (44,755,060 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- SEC Form SC 13D/A filed by Seagen Inc. (Amendment)
- Himes Vaughn B returned $30,765,005 worth of shares to the company (134,345 units at $229.00), closing all direct ownership in the company (SEC Form 4)
- Simonian Nancy A returned $14,370,437 worth of shares to the company (62,753 units at $229.00), closing all direct ownership in the company (SEC Form 4)